Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor Treating Fields (TTFields) demonstrate antiviral functions in vitro, and safety for application to COVID-19 patients in a pilot clinical study.
Abutbul A, Mumblat H, Porat Y, Friedman N, Atari N, Sharabi S, Nama A, Mugahed W, Kessler A, Kolben Y, Shamir RR, Manzur D, Farber O, Bosch L, Lavy-Shahaf G, Dor-On E, Haber A, Giladi M, Weinberg U, Palti Y, Mardor Y, Mandelboim M. Abutbul A, et al. Among authors: dor on e. Front Microbiol. 2023 Nov 29;14:1296558. doi: 10.3389/fmicb.2023.1296558. eCollection 2023. Front Microbiol. 2023. PMID: 38094629 Free PMC article.
Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.
Mumblat H, Martinez-Conde A, Braten O, Munster M, Dor-On E, Schneiderman RS, Porat Y, Voloshin T, Davidi S, Blatt R, Shteingauz A, Tempel-Brami C, Zeevi E, Lajterer C, Shmueli Y, Danilov S, Haber A, Giladi M, Weinberg U, Kinzel A, Palti Y. Mumblat H, et al. Among authors: dor on e. Lung Cancer. 2021 Oct;160:99-110. doi: 10.1016/j.lungcan.2021.08.011. Epub 2021 Aug 27. Lung Cancer. 2021. PMID: 34482104 Free article.
Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo.
Davidi S, Jacobovitch S, Shteingauz A, Martinez-Conde A, Braten O, Tempel-Brami C, Zeevi E, Frechtel-Gerzi R, Ene H, Dor-On E, Voloshin T, Tzchori I, Haber A, Giladi M, Kinzel A, Weinberg U, Palti Y. Davidi S, et al. Among authors: dor on e. Cancers (Basel). 2022 Jun 15;14(12):2959. doi: 10.3390/cancers14122959. Cancers (Basel). 2022. PMID: 35740624 Free PMC article.
Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959.
Davidi S, Jacobovitch S, Shteingauz A, Martinez-Conde A, Braten O, Tempel-Brami C, Zeevi E, Frechtel-Gerzi R, Ene H, Dor-On E, Voloshin T, Tzchori I, Haber A, Giladi M, Kinzel A, Weinberg U, Palti Y. Davidi S, et al. Among authors: dor on e. Cancers (Basel). 2023 Feb 13;15(4):1182. doi: 10.3390/cancers15041182. Cancers (Basel). 2023. PMID: 36831698 Free PMC article.
Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance.
Berckmans Y, Ene HM, Ben-Meir K, Martinez-Conde A, Wouters R, Van den Ende B, Van Mechelen S, Monin R, Frechtel-Gerzi R, Gabay H, Dor-On E, Haber A, Weinberg U, Vergote I, Giladi M, Coosemans A, Palti Y. Berckmans Y, et al. Among authors: dor on e. Front Oncol. 2024 Jun 27;14:1402851. doi: 10.3389/fonc.2024.1402851. eCollection 2024. Front Oncol. 2024. PMID: 38993641 Free PMC article.